Stay updated on Nivolumab and Ipilimumab in ACC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Ipilimumab in ACC Clinical Trial page.

Latest updates to the Nivolumab and Ipilimumab in ACC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe clinical trial record for nivolumab and ipilimumab in metastatic or recurrent salivary gland cancer is now displayed, with study details, participation criteria, outcome measures, and supporting documents.SummaryDifference63%

- Check20 days agoChange DetectedThe footer revision number changed from v3.7.2 to v3.8.0; the page remains a 403 Forbidden error.SummaryDifference0.2%

- Check27 days agoChange DetectedA site-wide notice says NIH is transitioning from using “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check34 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2 while the page continued to display a 403 error.SummaryDifference0.2%

- Check41 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1 on the 403 Forbidden page.SummaryDifference0.2%

- Check62 days agoChange DetectedThe study page renders a 403 Forbidden error instead of the usual content, replacing the study details and links with an access-denied message. This indicates a gating of the study record, hindering user access to the trial information.SummaryDifference21%

Stay in the know with updates to Nivolumab and Ipilimumab in ACC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Ipilimumab in ACC Clinical Trial page.